Physician profile
Rasheed Riad Zaid
NPI 1336370881
$9,265.84
in general payments reported to CMS, 2019-2025
39 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,178 · 2020: $1,217 · 2021: $859 · 2022: $1,912 · 2023: $1,748 · 2024: $1,099 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,099.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,388.12 | 2019-2025 | |
| Boston Scientific Corporation | $969.81 | 2019-2025 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $856.86 | 2021-2025 | Verquvo, Capvaxive, Januvia |
| Janssen Pharmaceuticals, INC | $805.19 | 2019-2023 | Xarelto |
| Abbott Laboratories | $654.03 | 2019-2024 | Aveir, Ensite, Merlin@Home |
| Bard Peripheral Vascular, INC. | $567.39 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $496.16 | 2022-2024 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $471.77 | 2019-2025 | Lifevest |
| Amgen INC. | $349.22 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $346.67 | 2019-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $237.43 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.42 | 2019-2025 | Jardiance |
| Pfizer INC. | $179.89 | 2020-2025 | |
| Abiomed | $162.00 | 2024 | Impella |
| Novo Nordisk INC | $157.08 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rasheed Zaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.